Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus

NCT01935453 is registered in ClinicalTrials.gov with OrienGene Biotechnology Ltd. as lead sponsor.

NCT NCT01935453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus
Lead sponsor
OrienGene Biotechnology Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2012
Completion date
Not reported
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer, lung cancer, melanoma, pancreatic cancer